Multiple sclerosis (MS) is most likely to adopt a progressive clinical course during middle age or beyond, and the number of older adults with MS is steadily increasing. Developing new strategies to manage progressive forms of MS, which do not respond to currently available disease-modifying therapies (DMTs), will require a deeper understanding of the mechanisms by which biological aging interacts with pathogenic pathways to propel disability accumulation. In experimental autoimmune encephalomyelitis (EAE), a widely used preclinical mouse model of MS, middle-aged animals experience a more severe and protracted clinical course than their younger counterparts. This exacerbated disease course is accompanied by persistent neuroinflammation. Clinical studies of age-related biomarkers, such as telomere length, senescence markers, and DNA methylation, suggest that biological aging is accelerated in people with MS compared with age- and sex-matched healthy controls. Furthermore, distinguishing biological age from chronological may afford more precision in determining aging effects in MS. Here we review the current literature on aging biology and its impact on MS pathogenesis. Future research on this topic may lead to the development of novel biomarkers and senotherapy agents that slow neurological decline in people with progressive MS by targeting relevant aging-related pathways.
WallinMTCulpepperWJCampbellJD, et al. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology2019; 92: e1029–e1040.
2.
DegenhardtARamagopalanSVScalfariA, et al. Clinical prognostic factors in multiple sclerosis: A natural history review. Nat Rev Neurol2009; 5: 672–682.
3.
SegalBM. CNS chemokines, cytokines, and dendritic cells in autoimmune demyelination. J Neurol Sci2005; 228: 210–214.
4.
ParkCPonathGLevine-RittermanM, et al. The landscape of myeloid and astrocyte phenotypes in acute multiple sclerosis lesions. Acta Neuropathol Commun2019; 7: 130.
5.
ScalfariALedererCDaumerM, et al. The relationship of age with the clinical phenotype in multiple sclerosis. Mult Scler2016; 22: 1750–1758.
6.
KochMWMostertJZhangY, et al. Association of age with contrast-enhancing lesions across the multiple sclerosis disease spectrum. Neurology2021; 97: e1334–e1342.
7.
GilesDAWashnock-SchmidJMDunckerPC, et al. Myeloid cell plasticity in the evolution of central nervous system autoimmunity. Ann Neurol2018; 83: 131–141.
8.
RissanenETuiskuJVahlbergT, et al. Microglial activation, white matter tract damage, and disability in MS. Neurol Neuroimmunol Neuroinflamm2018; 5: e443.
9.
MagliozziRHowellOVoraA, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain2007; 130: 1089–1104.
AtkinsonJRJeromeADSasAR, et al. Biological aging of CNS-resident cells alters the clinical course and immunopathology of autoimmune demyelinating disease. JCI Insight2022; 7: e158153.
12.
ZuoMFettigNMBernierLP, et al. Age-dependent gray matter demyelination is associated with leptomeningeal neutrophil accumulation. JCI Insight2022; 7: e158144.
13.
OlahMPatrickEVillaniAC, et al. A transcriptomic atlas of aged human microglia. Nat Commun2018; 9: 539
14.
SafaiyanSBesson-GirardSKayaT, et al. White matter aging drives microglial diversity. Neuron2021; 109: 1100–1117.e10.
15.
FernandezAQuintanaEVelascoP, et al. Senescent accelerated prone 8 (SAMP8) mice as a model of age dependent neuroinflammation. J Neuroinflammation2021; 18: 75.
HuberAKWangLHanP, et al. Dysregulation of the IL-23/IL-17 axis and myeloid factors in secondary progressive MS. Neurology2014; 83: 1500–1507.
18.
GyonevaSHosurRGosselinD, et al. Cx3cr1-deficient microglia exhibit a premature aging transcriptome. Life Sci Alliance2019; 2: e201900453.
19.
NordenDMGodboutJP. Review: Microglia of the aged brain: Primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol2013; 39: 19–34.
20.
RothhammerVBoruckiDMTjonEC, et al. Microglial control of astrocytes in response to microbial metabolites. Nature2018; 557: 724–728.
21.
Ruiz-RuizSSanchez-CarrilloSCiordiaS, et al. Functional microbiome deficits associated with ageing: Chronological age threshold. Aging Cell2020; 19: e13063.
22.
ThewissenMSomersVVenkenK, et al. Analyses of immunosenescent markers in patients with autoimmune disease. Clin Immunol2007; 123: 209–218.
23.
ThewissenMLinsenLSomersV, et al. Premature immunosenescence in rheumatoid arthritis and multiple sclerosis patients. Ann N Y Acad Sci2005; 1051: 255–262.
24.
MogilenkoDAShpynovOAndheyPS, et al. Comprehensive profiling of an aging immune system reveals clonal GZMK(+) CD8(+) T cells as conserved hallmark of inflammaging. Immunity2021; 54: 99–115.e12.
25.
KoetzierSCvan LangelaarJMeliefMJ, et al. Distinct effector programs of brain-homing CD8(+) T cells in multiple sclerosis. Cells2022; 11: 1634.
26.
BouwmanACvan DaalenKRCrnkoS, et al. Intracellular and extracellular roles of granzyme K. Front Immunol2021; 12: 677707.
27.
ZuroffLRezkAShinodaK, et al. Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age. EBioMedicine2022; 82: 104179.
28.
RawjiKSYoungAMHGhoshT, et al. Niacin-mediated rejuvenation of macrophage/microglia enhances remyelination of the aging central nervous system. Acta Neuropathol2020; 139: 893–909.
29.
SimFJZhaoCPenderisJ, et al. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci2002; 22: 2451–2459.
30.
ShenSSandovalJSwissVA, et al. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat Neurosci2008; 11: 1024–1034.
31.
NeumannBBarorRZhaoC, et al. Metformin restores CNS remyelination capacity by rejuvenating aged stem cells. Cell Stem Cell2019; 25: 473–485.e8.
32.
ProzorovskiTIngwersenJLukasD, et al. Regulation of sirtuin expression in autoimmune neuroinflammation: Induction of SIRT1 in oligodendrocyte progenitor cells. Neurosci Lett2019; 704: 116–125.
33.
JylhavaJPedersenNLHaggS. Biological age predictors. EBioMedicine2017; 21: 29–36.
34.
ArmaniosMBlackburnEH. The telomere syndromes. Nat Rev Genet2012; 13: 693–704.
35.
ArmaniosM. Telomeres and age-related disease: How telomere biology informs clinical paradigms. J Clin Invest2013; 123: 996–1002.
36.
BuhringJHeckerMFitznerB, et al. Systematic review of studies on telomere length in patients with multiple sclerosis. Aging Dis2021; 12: 1272–1286.
37.
KryskoKMHenryRGCreeBAC, et al. Telomere length is associated with disability progression in multiple sclerosis. Ann Neurol2019; 86: 671–682.
38.
HorvathSRajK. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet2018; 19: 371–384.
39.
LevineMELuATQuachA, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY)2018; 10: 573–591.
40.
ChenBHMarioniREColicinoE, et al. DNA methylation-based measures of biological age: Meta-analysis predicting time to death. Aging (Albany NY)2016; 8: 1844–1865.
41.
MarioniREShahSMcRaeAF, et al. DNA methylation age of blood predicts all-cause mortality in later life. Genome Biol2015; 16: 25.
42.
TheodoropoulouEAlfredssonLPiehlF, et al. Different epigenetic clocks reflect distinct pathophysiological features of multiple sclerosis. Epigenomics2019; 11: 1429–1439.
43.
KularLKloseDUrdanoz-CasadoA, et al. Epigenetic clock indicates accelerated aging in glial cells of progressive multiple sclerosis patients. Front Aging Neurosci2022; 14: 926468.
44.
HugAKorporalMSchroderI, et al. Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis. J Immunol2003; 171: 432–437.
45.
GravesJSHenryRGCreeBAC, et al. Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology2018; 90: e254–e260.
46.
ChaibSTchkoniaTKirklandJL. Cellular senescence and senolytics: The path to the clinic. Nat Med2022; 28: 1556–1568.
47.
HuWTHowellJCOzturkT, et al. CSF cytokines in aging, multiple sclerosis, and dementia. Front Immunol2019; 10: 480.
48.
PerdaensOvan PeschV. Molecular mechanisms of immunosenescene and inflammaging: Relevance to the immunopathogenesis and treatment of multiple sclerosis. Front Neurol2021; 12: 811518.
49.
HallBMBalanVGleibermanAS, et al. P16(Ink4a) and senescence-associated beta-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli. Aging (Albany NY)2017; 9: 1867–1884.
50.
LiuYSanoffHKChoH, et al. Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell2009; 8: 439–448.
51.
Lopez-OtinCBlascoMAPartridgeL, et al. The hallmarks of aging. Cell2013; 153: 1194–1217.
52.
FerrucciLGonzalez-FreireMFabbriE, et al. Measuring biological aging in humans: A quest. Aging Cell2020; 19: e13080.
53.
SierraFKohanskiR. Geroscience and the trans-NIH Geroscience Interest Group, GSIG. Geroscience2017; 39: 1–5.
